US Patent Issued to NANJING IASO BIOTECHNOLOGY on June 9 for "Fully humanized bispecific chimeric antigen receptor targeting CD19 and CD22 and use thereof" (Chinese Inventors)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,648,995, issued on June 9, was assigned to NANJING IASO BIOTECHNOLOGY Co. LTD. (Nanjing, China).

"Fully humanized bispecific chimeric antigen receptor targeting CD19 and CD22 and use thereof" was invented by Yongkun Yang (Nanjing, China), Guang Hu (Nanjing, China), Taochao Tan (Nanjing, China), Zhenyu Dai (Nanjing, China), Panpan Niu (Nanjing, China), Guangrong Meng (Nanjing, China), Wei Cheng (Nanjing, China), Xiangyin Jia (Nanjing, China), Jialu Mo (Nanjing, China), Wen Wang (Nanjing, China), Bailu Xie (Nanjing, China), Junfeng Yang (Nanjing, China) and Fei Zhou (Nanjing, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is a bispecific chi...